No Detail Found!

Prognostic Markers after Hepatic Function Impairment in Patients with Pancreatic Adenocarcinoma

Author(s)
Mustafa Buyukkor Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
Fatih Tay Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
Cengiz Karacin Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
Ayse Ocak Duran Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
Abstract
Objective: To determine the factors a ecting survival after hepatic failure in patients with pancreatic adenocarcinoma (PAC) who developed hepatic dysfunction accompanied by hyperbilirubinemia. Study Design: Observational Study. Place and Duration of Study: Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey, from January 2017 to May 2022. Methodology: The clinical characteristics of adult patients who developed hepatic dysfunction accompanied by hyperbilirubinemia with a diagnosis of PAC and died in their follow-up were recorded from the hospital's patient registry database. Patients without medical record were excluded. The e ective parameters of overall survival after hepatic failure (aHFOS) were determined. Results: The study included 57 patients with PAC (56.1% males) who developed hepatic dysfunction during their follow-up. According to the CA 19-9 value at the time of diagnosis, the tumour localisation was predicted to be located in the head and neck (Cuto d1400, AUC 0.77, sensitivity 73.2%, speci city 75%; p=0.002). Values of international normalised ratio (INR, p=0.010), blood urea nitrogen (BUN, p=0.002) that were measured during hepatic dysfunction, and tumour location in the head and neck in the pancreas (p=0.028) were determined as independent variables a ecting aHFOS in patients with PAC. In addition, percutaneous transhepatic biliary drainage (PTDB) application during liver failure and initiation of chemotherapy in appropriate patients also positively a ected aHFOS (2.62 months vs. 0.92 months, p=0.016 and 3.45 months vs. 1.11 months, p=0.003; respectively). Conclusion: Su cient liver function reserve in malignant patients is highly e ective in the curability and survival of patients. In this regard, it is crucial to improve prognosis by identifying the factors a ecting aHFOS in patients with PAC who develop hepatic dysfunction due to liver metastasis or the primary tumour characteristics.
Publication Details
Page(s) 36-40
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Prognosis, survival, CA 19-9, Pancreatic adenocarcinoma, Hepatic failure
0

Citations

0

Downloads

62

Views